- Home
- ADPT vs ALVO Comparison
ADPT vs ALVO Comparison
Compare ADPT & ALVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADPT
- ALVO
- Stock Information
- Founded
- ADPT 2009
- ALVO 2013
- Country
- ADPT United States
- ALVO Luxembourg
- Employees
- ADPT N/A
- ALVO N/A
- Industry
- ADPT Biotechnology: Biological Products (No Diagnostic Substances)
- ALVO Biotechnology: Pharmaceutical Preparations
- Sector
- ADPT Health Care
- ALVO Health Care
- Exchange
- ADPT Nasdaq
- ALVO Nasdaq
- Market Cap
- ADPT 2.6B
- ALVO 2.5B
- IPO Year
- ADPT 2019
- ALVO N/A
- Fundamental
- Price
- ADPT $16.88
- ALVO $4.82
- Analyst Decision
- ADPT Strong Buy
- ALVO Buy
- Analyst Count
- ADPT 10
- ALVO 2
- Target Price
- ADPT $15.10
- ALVO $11.00
- AVG Volume (30 Days)
- ADPT 1.5M
- ALVO 630.1K
- Earning Date
- ADPT 11-05-2025
- ALVO 11-12-2025
- Dividend Yield
- ADPT N/A
- ALVO N/A
- EPS Growth
- ADPT N/A
- ALVO N/A
- EPS
- ADPT N/A
- ALVO 0.22
- Revenue
- ADPT $205,216,000.00
- ALVO $562,478,000.00
- Revenue This Year
- ADPT $34.41
- ALVO $34.94
- Revenue Next Year
- ADPT $14.03
- ALVO $39.55
- P/E Ratio
- ADPT N/A
- ALVO $22.21
- Revenue Growth
- ADPT 21.60
- ALVO 82.19
- 52 Week Low
- ADPT $4.27
- ALVO $4.70
- 52 Week High
- ADPT $17.89
- ALVO $13.70
- Technical
- Relative Strength Index (RSI)
- ADPT 59.44
- ALVO 17.12
- Support Level
- ADPT $16.59
- ALVO $7.77
- Resistance Level
- ADPT $17.76
- ALVO $8.50
- Average True Range (ATR)
- ADPT 0.77
- ALVO 0.34
- MACD
- ADPT -0.09
- ALVO -0.37
- Stochastic Oscillator
- ADPT 50.12
- ALVO 1.98
About ADPT Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).
About ALVO Alvotech
Alvotech is an integrated biopharmaceutical company committed to developing and manufacturing high-quality biosimilar medicines for patients globally. its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases.